Targeted Oncology

Targeted Oncology

http://springerlink.com/content/119822/

Publisher: Springer Paris

Despite the major efforts made in oncology over the past ten years, only
relatively modest improvements have been made in the conventional treatment
of cancer. Recently, a better understanding of molecular pathways has
provided pathologists with clues to the parthenogenesis of the disease and
multiple targets for new strategies.

New treatments, monoclonal antibodies or small molecules, have emerged
targeting these pathways and inhibiting tumor growth and progression. These
"mabs" and "nibs" constitute a new language with its own grammar that
oncologists have to learn. Significant work remains in controlling theses
processes and understanding these new compounds.

This journal aims to be a pragmatic tool for all physicians committed to the
field, focusing on insight into the basic science of cellular functions,
critical reviews of clinical data, and digests of the main meetings.

ISSN 1776-2596 (Print)
ISSN 1776-260X (Online)

Editor-in-Chief: 

Jean-François Morère
Bobigny, France

Email: jean-francois.morere@avc.ap-hop-paris.fr

Content available by subscription. Free content available online.
 
Abstracts available online. Articles available in HTML and PDF format.
 
Current Issue: Volume 2, Number 3 / July 2007

Date: 16 October 2007